PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Sees Significant Drop in Short Interest

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 51,900 shares, a decline of 15.9% from the October 31st total of 61,700 shares. Based on an average trading volume of 34,700 shares, the short-interest ratio is currently 1.5 days. Approximately 0.7% of the company’s stock are sold short.

PharmaCyte Biotech Price Performance

PMCB opened at $1.71 on Friday. PharmaCyte Biotech has a fifty-two week low of $1.39 and a fifty-two week high of $2.58. The firm has a market capitalization of $13.13 million, a PE ratio of 2.61 and a beta of -0.20. The company’s 50-day moving average is $1.77 and its 200 day moving average is $1.89.

PharmaCyte Biotech (NASDAQ:PMCB) last issued its quarterly earnings data on Monday, September 16th. The company reported $0.14 EPS for the quarter.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.